ImmunityBio

ImmunityBio Secures Macau Approval for ANKTIVA® to Treat BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors

ImmunityBio Secures Macau SAR Authorization for ANKTIVA® in BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors ImmunityBio, today announced that the Pharmaceutical Administration Bureau (ISAF) of the Macau Special…

Read MoreImmunityBio Secures Macau Approval for ANKTIVA® to Treat BCG-Unresponsive NMIBC with CIS With or Without Papillary Tumors

Newron to Showcase Latest Advances at the 2026 Schizophrenia International Research Society Annual Congress 2026

Newron Showcases Latest Research at the 2026 Schizophrenia International Research Society Annual Congress 2026 Newron Pharmaceuticals S.p.A., a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for disorders affecting the…

Read MoreNewron to Showcase Latest Advances at the 2026 Schizophrenia International Research Society Annual Congress 2026

TALZENNA Combination with XTANDI Demonstrates Significant Improvement in Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TALZENNA in Combination with XTANDI Shows Marked Improvement in Radiographic Progression-Free Survival for Patients with Metastatic Prostate Cancer Pfizer Inc. has announced compelling topline results from its Phase 3 TALAPRO-3…

Read MoreTALZENNA Combination with XTANDI Demonstrates Significant Improvement in Radiographic Progression-Free Survival in Metastatic Prostate Cancer